.. -19 2,500 11 .. " " .. -19 " 2,500 . tixagevimab/cilgavimab () 6 (US FDA) 608 5,172 6 -19 80% 12 https://www.ncbi.nlm.nih.gov/.../41591_2021_Article_1678.p 25-140 https://www.ncbi.nlm.nih.go… [+148 chars]
(%) 100,000 - (person-days) ( "-" - - -) "" (absolute risk reduction – ARR) 3.9 100,000 - (0.0039%) 1.5 100,000 (0.0015%) 0.0024% ( 100 -) 0.0024% 1.2. (exclude) ( exclude ) 1. WHO 3.0… [+560 chars]
.. -19 2,500 11 .. " " .. -19 " 2,500 . tixagevimab/cilgavimab () 6 (US FDA) 608 5,172 6 -19 80% 12 https://www.ncbi.nlm.nih.gov/.../41591_2021_Article_1678.p 25-140 https://www.ncbi.nlm.nih.go… [+148 chars]
1. 2. 3. herpesviruses "Long COVID" 4. Microbiome 5. 6. SARS-CoV-2
-19 11 .. 65 22,387 27,680 105 -19
MGR Online - . 50 (11 ..) .. 13.30 . .. 35 10 ... . .4 .. .. () .. .. -19 64 .. 300 20-25 1 64 .. 50 50
-19 11 .. 65 22,387 27,680 105 -19
COVID-19 (Long Covid) -19 2 6 1. 44.38% 2 32.1% 3. 27.33% 4. 22.86% 5. 22.8% 6. 23.41% 2 # # #19 CR: COVID-19
"" 11 ..65 .. 2,500 . tixagevimab/cilgavimab () 6 (US FDA) 608 5,172 6 -19 80% 12 https://www.ncbi.nlm.nih.gov/.../41591_2021_Article_1678.p 25-140 https://www.ncbi.nlm.nih.gov/...… [+138 chars]
. 10 ATK 10 .. . () (.) Anan Jongkaewwattana 10 . “ 10 10 ”” RT-PCR 30 ATK ” “ RT-PCR 30 ATK 9 RT-PCR Ct 29 ( BA.2) 32 11 Ct 20-25 4 22 18.18% ATK ” “ 10 ATK ATK ” BA.1, BA.1.1 BA.2 3 82 ( 2… [+131 chars]
60 . “” (Dopamine) 60 1.5 . 3 1. 2. 3. “ 11 ” “ ?” NIT Talk EP.80 Facebook Live
60 . “” (Dopamine) 60 1.5 . 3 1. 2. 3. “ 11 ” “ ?” NIT Talk EP.80 Facebook Live
